T. Bush

发表

Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant human malaria parasites (Plasmodium falciparum) in vitro and in combination with alpha-difluoromethylornithine cure murine malaria.

A. Bitonti, J. Dumont, T. Bush, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Discovery and evaluation of dual CDK1 and CDK2 inhibitors.

Juan Leal, Richard Kendall, T. Bush, 2006, Cancer research.

Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions.

T. Bush, M. Espeland, M. Stefanick, 1995, Controlled clinical trials.

Macronutrient intakes among adult Hispanics: a comparison of Mexican Americans, Cuban Americans, and mainland Puerto Ricans.

C. Loria, M. Carroll, M. McDowell, 1995, American journal of public health.

AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues

Connie Y. C. Ma, T. Bush, R. Loberg, 2014, Journal of Translational Medicine.

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

P. Gallant, T. Bush, M. Morrison, 2010, Journal of medicinal chemistry.

Antitrypanosomal effects of polyamine biosynthesis inhibitors correlate with increases in Trypanosoma brucei brucei S-adenosyl-L-methionine.

A. Bitonti, T. Bush, P. McCann, 1991, The Biochemical journal.

The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.

T. Bush, M. Rong, K. Sham, 2013, Bioorganic & medicinal chemistry letters.

Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.

T. Bush, A. Cheng, D. Whittington, 2011, Bioorganic & medicinal chemistry letters.

Measurement of mRNA levels in tumor xenografts with quantitative autoradiography and in situ hybridization

A. Bitonti, T. Bush, P. Wright, 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Molecular Cancer Therapeutics.

Title: Discovery of JNJ-63576253, a next-generation androgen receptor antagonist active against wild- type and clinically-relevant ligand binding domain mutations in metastatic castration-resistant prostate cancer (mCRPC) Running Title: Discovery of JNJ-63576253, a next-generation AR antagonist

Yolanda T. Chong, T. Bush, G. Bignan, 2021 .

Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

T. Bush, Grace Chung, R. Radinsky, 2015, Journal of Medicinal Chemistry.

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

T. Bush, A. Coxon, R. Radinsky, 2013 .

In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor.

A. Bitonti, T. Bush, S. Schold, 1996, Cancer research.

Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase.

A. Bitonti, T. Bush, P. Sunkara, 1995, Anticancer research.

Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase.

A. Bitonti, J. Dumont, T. Bush, 1994, Cancer research.

Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase

A. Bitonti, T. Bush, P. McCann, 1990, Antimicrobial Agents and Chemotherapy.

Clomiphene analogs with activity in vitro and in vivo against human breast cancer cells.

G. F. Davis, A. Bitonti, T. Bush, 1998, Biochemical pharmacology.

AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models

T. Bush, R. Loberg, Marc Payton, 2013, Molecular Cancer Therapeutics.

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

T. Bush, Marc Payton, Grace Chung, 2010, Cancer research.

Therapeutics , Targets , and Chemical Biology Preclinical Evaluation of AMG 900 , a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

T. Bush, Marc Payton, Grace Chung, 2010 .

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Journal of medicinal chemistry.

ResearchMotesanib inhibits Kit mutations associated with gastrointestinal stromal tumors

T. Bush, A. Tasker, T. Juan, 2015 .

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors

Todd Juan, Will Baron, T. Bush, 2010, Journal of experimental & clinical cancer research : CR.

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors

Paul Hughes, Richard Kendall, T. Bush, 2009, Clinical Cancer Research.

BroadAntitumorActivity inBreastCancerXenograftsbyMotesanib , aHighly Selective , Oral Inhibitorof Vascular Endothelial Growth Factor , Platelet-DerivedGrowth Factor , andKit Receptors

T. Bush, K. Rex, A. Coxon, 2008 .

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

Daniel J. Freeman, Todd Juan, T. Bush, 2009, Molecular Cancer Therapeutics.

Regulation of polyamine biosynthesis in rat hepatoma (HTC) cells by a bisbenzyl polyamine analogue.

A. Bitonti, T. Bush, P. McCann, 1989, The Biochemical journal.

The potential role of respiratory therapy equipment in cross infection. A study using a canine model for pneumonia.

T. Bush, L. Saravolatz, W. Conway, 1983, The American review of respiratory disease.

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.

T. Bush, Tzu-Hsuan Huang, D. Branstetter, 2014, Cancer cell.

Bis(benzyl)polyamine analogs as novel substrates for polyamine oxidase.

A. Bitonti, J. Dumont, T. Bush, 1990, The Journal of biological chemistry.

Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.

T. Bush, M. Espeland, R. Sherwin, 1998, Circulation.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

T. Bush, A. Cheng, P. Andrews, 2012, Bioorganic & medicinal chemistry letters.

Abstract 1256: JNJ-74856665, a novel DHODH inhibitor, mediates potent anti-leukemic activity and differentiationin vitroandin vivo

E. Jacoby, T. Bush, S. Kuduk, 2021, Experimental and Molecular Therapeutics.

Agreement in assessing endometrial pathology: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.

T. Bush, M. Espeland, G. Greendale, 1998, Journal of women's health.

Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731).

A. Bitonti, T. Bush, P. Wright, 1997, Oncology research.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

Daniel J. Freeman, T. Bush, R. Radinsky, 2009, Molecular Cancer Therapeutics.